Targeting Shared Risk Pathways to Prevent Stroke, Dementia, and Depression

By Rene Pretorius

April 23, 2025

This review examines a systematic study identifying 17 modifiable risk factors linked to stroke, dementia, and late-life depression (LLD) through shared risk pathways. Published in Journal of Neurology, Neurosurgery & Psychiatry (2025), the research offers critical insights for health policy executives and pharmaceutical leaders. By targeting shared risk pathways, stakeholders can promote healthy aging and build cost-effective healthcare systems. The study’s findings provide an evidence-based foundation for preventive strategies, addressing the rising burden of age-related brain diseases.

Background: The Need for Targeting Shared Modifiable Risk Pathways

Neurological and mental disorders account for a significant portion of the global disease burden. Stroke and dementia rank among the top causes of disability in older adults, while late-life depression (LLD) exacerbates healthcare challenges. The World Health Organization (WHO) emphasizes that modifying risk factors—such as hypertension, smoking, and sedentary lifestyles—can prevent up to 40% of dementia cases and reduce stroke incidence. Aging populations strain healthcare systems, with costs projected to exceed $1 trillion annually by 2050 for dementia alone. Current tools, like cardiovascular risk scores, often overlook shared risk pathways across brain diseases. This gap underscores the urgent need for holistic, cost-effective interventions targeting shared modifiable risk pathways to promote brain health.

Main Results: Key Modifiable Risk Factors for Brain Health

The systematic review analyzed 59 meta-analyses, identifying 17 modifiable risk factors for brain health. These factors influence stroke, dementia, and LLD, offering opportunities for integrated prevention.

  • High Blood Pressure: Hypertension (≥140/90 mm Hg) showed the strongest effect, with a relative risk (RR) of 2.68 for stroke and 1.20 for dementia. Managing blood pressure could significantly reduce disease incidence.

  • Kidney Function: Severe kidney disease (eGFR <30 mL/min/1.73 m²) increased stroke risk (RR: 1.70) and dementia risk (RR: 1.91). Early interventions targeting kidney health may yield broad benefits.

  • Smoking: Current smoking raised stroke risk (RR: 1.54–1.64) and dementia risk (RR: 1.27–1.30). Smoking cessation programs could lower disease burden.

  • Physical Activity: Moderate to high physical activity reduced stroke risk (RR: 0.64–0.85) and dementia risk (RR: 0.63–0.80). Exercise programs are cost-effective for prevention.

  • Diet: Adherence to AHA-recommended diets, like DASH, lowered stroke and dementia risks. Nutritional interventions offer scalable solutions.

  • Social Engagement: Social isolation increased stroke risk (RR: 1.32) and dementia risk (RR: 1.23–1.58). Community-based programs can enhance brain health.

  • Other Factors: Cognitive activity (RR: 0.61 for dementia), sleep quality (RR: 1.47–1.51 for insomnia), and stress (RR: 1.33–1.44) also showed significant effects. Holistic interventions addressing these factors can amplify impact.

The study calculated disability-adjusted life year (DALY)-weighted effect sizes, revealing shared risk pathways. Addressing one factor, like hypertension, may reduce risks across all three conditions, maximizing preventive impact.

Conclusion: Leveraging Shared Risk Pathways for Cost-Effective Healthcare and Healthy Aging

This study underscores the power of shared risk pathways in addressing modifiable risk factors for brain health. By targeting common risks like hypertension, smoking, and low physical activity, health policy executives can reduce the incidence of stroke, dementia, and LLD simultaneously. These shared pathways enable cost-effective interventions, potentially saving billions annually, with dementia care costs alone projected to reach $600 billion in the U.S. by 2030. Tools like the Brain Care Score, built on these findings, guide precise prevention strategies. Pharmaceutical leaders can prioritize therapies for hypertension and kidney health, while community programs promoting exercise, healthy diets, and social engagement offer scalable solutions. By focusing on shared risk pathways, stakeholders can foster healthy aging, alleviate disease burden, and create sustainable healthcare systems.

Reference url

Recent Posts

preventive health costs
       

Prevention Valuation: Fund Health, Not Just Savings

💡 Is prevention really saving us money in healthcare?

In their thought-provoking article, “Can Prevention Save Money?”, Baicker and Chandra challenge the prevailing notion that preventive health measures always reduce costs. They argue that while prevention can enhance health outcomes, it often leads to increased spending upfront, and the key lies in evaluating these programs based on their cost-effectiveness instead of expecting them to save money outright.

Curious about the real financial implications of preventive care? Dive into the full analysis to uncover the nuances!

#SyenzaNews #HealthEconomics #costeffectiveness #healthcarepolicy

FDA AI Drug Approval
          

FDA AI Drug Approval

🚀 Are we on the brink of a new era in drug approval?

The FDA’s new AI initiative is set to reshape how we evaluate new therapies by dramatically speeding up the review process. With generative AI tools already cutting down review times from days to mere minutes, this breakthrough will not only enhance efficiency but also enable scientists to focus on more impactful work.

Curious about the implications for market access, patient outcomes, and health economics? Dive into the full article to explore how the future of pharmaceutical approvals is being transformed!

#SyenzaNews #regulatoryaffairs #AIinHealthcare #innovation

HCV treatment advancements
      

HCV Treatment Advancements: Atea Pharmaceuticals KOL Panel

🌍 Are we on the brink of a new era in Hepatitis C treatment?

Atea Pharmaceuticals is hosting a virtual KOL panel on May 14, 2025, featuring top experts discussing the challenges faced by HCV patients and sharing insights from the promising results of their Phase 2 study on bemnifosbuvir and ruzasvir. This could be a game-changer in advancing HCV treatments through ongoing Phase 3 trials.

Don’t miss out on how these developments might reshape the future landscape for HCV patients! Click to read more about the panel and the innovative therapies in the pipeline.

#SyenzaNews #biotechnology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.